USNA Valuation

USANA Health Sciences Inc

Add to Watchlist

Advanced Chart

32.240

+1.61(5.256%)1D

Overview
Forecast
Valuation
Earnings

USNA Relative Valuation

USNA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, USNA is overvalued; if below, it's undervalued.

Historical Valuation

USANA Health Sciences Inc (USNA) is now in the Undervalued zone, suggesting that its current forward PE ratio of 11.44 is considered Undervalued compared with the five-year average of 17.56. The fair price of USANA Health Sciences Inc (USNA) is between 46.17 to 63.97 according to relative valuation methord. Compared to the current price of 32.15 USD , USANA Health Sciences Inc is Undervalued By 30.36%.

Relative Value

Fair Zone

46.17-63.97

Current Price：32.15

30.36%

Undervalued

11.26

Trailing

Forward

4.04

EV/EBITDA

USANA Health Sciences Inc. (USNA) has a current EV/EBITDA of 4.04. The 5-year average EV/EBITDA is 7.02. The thresholds are as follows: Strongly Undervalued below 2.24, Undervalued between 2.24 and 4.63, Fairly Valued between 9.40 and 4.63, Overvalued between 9.40 and 11.79, and Strongly Overvalued above 11.79. The current Forward EV/EBITDA of 4.04 falls within the Undervalued range.

7.90

EV/EBIT

USANA Health Sciences Inc. (USNA) has a current EV/EBIT of 7.90. The 5-year average EV/EBIT is 9.16. The thresholds are as follows: Strongly Undervalued below 3.94, Undervalued between 3.94 and 6.55, Fairly Valued between 11.77 and 6.55, Overvalued between 11.77 and 14.38, and Strongly Overvalued above 14.38. The current Forward EV/EBIT of 7.90 falls within the Historic Trend Line -Fairly Valued range.

0.58

USANA Health Sciences Inc. (USNA) has a current PS of 0.58. The 5-year average PS is 1.23. The thresholds are as follows: Strongly Undervalued below 0.50, Undervalued between 0.50 and 0.86, Fairly Valued between 1.59 and 0.86, Overvalued between 1.59 and 1.96, and Strongly Overvalued above 1.96. The current Forward PS of 0.58 falls within the Undervalued range.

7.20

P/OCF

USANA Health Sciences Inc. (USNA) has a current P/OCF of 7.20. The 5-year average P/OCF is 12.05. The thresholds are as follows: Strongly Undervalued below 3.00, Undervalued between 3.00 and 7.53, Fairly Valued between 16.57 and 7.53, Overvalued between 16.57 and 21.10, and Strongly Overvalued above 21.10. The current Forward P/OCF of 7.20 falls within the Undervalued range.

8.86

P/FCF

USANA Health Sciences Inc. (USNA) has a current P/FCF of 8.86. The 5-year average P/FCF is 13.42. The thresholds are as follows: Strongly Undervalued below -3.25, Undervalued between -3.25 and 5.08, Fairly Valued between 21.75 and 5.08, Overvalued between 21.75 and 30.09, and Strongly Overvalued above 30.09. The current Forward P/FCF of 8.86 falls within the Historic Trend Line -Fairly Valued range.

USANA Health Sciences Inc (USNA) has a current Price-to-Book (P/B) ratio of 1.07. Compared to its 3-year average P/B ratio of 1.92 , the current P/B ratio is approximately -44.33% higher. Relative to its 5-year average P/B ratio of 2.91, the current P/B ratio is about -63.28% higher. USANA Health Sciences Inc (USNA) has a Forward Free Cash Flow (FCF) yield of approximately 9.02%. Compared to its 3-year average FCF yield of 7.44%, the current FCF yield is approximately 21.22% lower. Relative to its 5-year average FCF yield of 7.44% , the current FCF yield is about 21.14% lower.

1.05

P/B

Median3y

1.92

Median5y

2.91

8.97

FCF Yield

Median3y

7.44

Median5y

7.44

Competitors Valuation Multiple

The average P/S ratio for USNA's competitors is 4.01, providing a benchmark for relative valuation. USANA Health Sciences Inc Corp (USNA) exhibits a P/S ratio of 0.58, which is -85.54% above the industry average. Given its robust revenue growth of 10.79%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

USNA.N

USANA Health Sciences Inc

Niagen Bioscience Inc

Nature's Sunshine Products Inc

Performance Decomposition

Market capitalization of USNA decreased by 21.02% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 212.87M to 235.85M.

The secondary factor is the Margin Expansion, contributed -9.59%to the performance.

Overall, the performance of USNA in the past 1 year is driven by Revenue Growth. Which is more sustainable.

10.79%

212.87M → 235.85M

Revenue Growth

-9.59%

4.90 → 4.43

Margin Expansion

-22.22%

21.92 → 17.05

P/E Change

-21.02%